How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

445 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. HIV, viral hepatitis and STIs - a guide for primary care

infection and are characterised by hypermutability and quasi species. ? The microbiological and virological agents that cause STIs are highly diverse, having specific epidemiological profiles, varied modes of sexual transmission, different natural histories and individual treatment modalities. ? HIV is transmitted through sexual contact, blood-to-blood contact and mother-to-child transmission. Without treatment, most individuals with HIV develop severe immune deficiency within 10 years. Combination (...) antiretroviral therapy has transformed the course of the disease, extending the life expectancy of individuals with HIV by many years. ? STIs have a complex synergistic relationship with HIV. Most STIs play an enhancing role in the acquisition and transmission of HIV, while HIV may alter the natural history and response to treatment of some STIs. ? HBV is transmitted through mucous membrane contact (including unprotected sexual contact), blood-to-blood contact, mother-to-child transmission and intrafamilial

2014 Clinical Practice Guidelines Portal

102. VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions. Condition or disease (...) : resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment (VGX-3100, electroporation) Patients receive HPV DNA plasmids therapeutic vaccine VGX-3100 IM and then undergo electroporation over 10 seconds for 4 doses in week 0, 4, 12, and 24 in the absence of disease progression or unacceptable toxicity. Device: Electroporation Undergo electroporation Other Names: electroporation therapy EPT Biological: HPV DNA Plasmids Therapeutic Vaccine VGX-3100 Given IM Other Name: VGX

2018 Clinical Trials

103. Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

therapy known to interfere with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrolment) received such therapy, or has received 2 or more courses of high dose corticosteroids (≥20mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to enrolment. Subjects using inhaled, nasal, or topical corticosteroids (...) are considered eligible for the study Exclusion criterion only for SOT patients: Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (tumour necrosis factor-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]) ,intravenous gamma globulin or antilymphocyte sera. Subject has received any immune globulin or blood-derived

2018 Clinical Trials

104. Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

or subcutaneous immunoglobulin supplementation, radiation therapy, or immunomodulatory treatment within the previous 6 months (presence of precancerous lesions is not exclusionary Receipt of an investigational vaccine within 2 weeks of day 0. Receipt of ACIP recommended immunizations within 1 week of day 0. Any condition that, in the opinion of the investigator, contraindicates participation in this study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about (...) warts, lesions, and cancers. ICL is idiopathic CD4 T cell lymphocytopenia. People with this rare disease get more HPV-related diseases than other people do. The diseases are more severe and harder to treat in people with ICL. Researchers want to see if the vaccine GARDASIL 9 can help people with ICL. Objective: To study the effects of the vaccine GARDASIL 9 in people with ICL. Eligibility: Adults ages 18-60 with ICL Healthy volunteers the same age Design: Participants will be screened

2018 Clinical Trials

105. Cantharidin and Occlusion in Verruca Epithelium

, using the VP-102 applicator. Drug: VP-102-cantharidin topical film forming solution VP-102 cantharidin topical film forming solution. Other Name: Subjects will receive treatment to their warts with VP-102 Device: VP-102 Applicator The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device. Outcome Measures Go to Primary Outcome Measures : Cohort 1-Proportion of subjects exhibiting complete clearance of all (...) with the study results or place the subject at undue risk. (e.g., human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes). NOTE: Immunizations and flu shots may be administered throughout the study, but not within 5 days before or after treatment. Have more than 6 common warts at baseline. Present with any verruca plana, mosaiform, filoform, subungual (under the nail), genital or anal warts. In Cohort 2, subjects with periungual warts are also excluded. Have any

2018 Clinical Trials

106. A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

history of abnormal Pap test. History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer. Undergone hysterectomy (either vaginal or total abdominal hysterectomy). Receiving or has received in the year prior to Day 1 vaccination an excluded immunosuppressive therapy. A participant will be excluded if she is currently receiving steroid therapy, has recently received such therapy, or has received 2 or more courses (...) of corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal or topical steroids are considered eligible for the study. Received immune globulin product or blood-derived product within 6 months prior to Day 1 vaccination, or plans to receive any such product during the study. Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo. Received

2018 Clinical Trials

107. Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine in HIV and Transplant Patients

with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrolment) received such therapy, or has received 2 or more courses of high dose corticosteroids (≥20mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to enrolment. Subjects using inhaled, nasal, or topical corticosteroids are considered eligible for the study (...) Exclusion criterion only for SOT patients: Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, methotrexate, any chemotherapy, leflunomide (tumour necrosis factor-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]) ,intravenous gamma globulin or antilymphocyte sera. Subject has received any immune globulin or blood-derived product within the 3 months prior to the Day 1 vaccination

2018 Clinical Trials

108. In-use Study of Four Different Tampons

the immune system functions; including cancer, anemia, leukopenia, leukocyte function deficiency, malnutrition, or chemical dependence (e.g. opiates, marijuana etc.) (self-reported); have clinically diagnosed genital warts, lesions, and/or vaginal infections (such as bacterial vaginosis (BV), Candida spp., Trichomonas vaginalis) at the screening visit; have clinically diagnosed active or vaginal infections (Chlamydia trachomatis and/or Neisseria gonorrhoeae) identified through lab results from (...) 6 months; are pregnant (per urine pregnancy test at screening), or intend to become pregnant in the next 5 months; have a history of Toxic Shock Syndrome (TSS); have a history of heart valve replacement; have had an abnormal Pap in either of your last 2 Pap Smears; have taken steroids (systemic and/or topical), corticosteroids, antihistamines, and/or anti-inflammatories within the past seven days (excludes hormonal contraception); have a history of immunosuppressive drug therapy, chemotherapy

2018 Clinical Trials

109. Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

) or corticosteroids CYP3A inducer(s) and/or inhibitor(s) as specified in the MTN-033 Study Specific Procedures (SSP) Manual Hormone-replacement therapy in tablet, patch, injectable or gel form Known adverse reaction to any of the components of the study product, applicator or coital simulation device Use of pre-exposure prophylaxis (PrEP) for HIV prevention within 1 month prior to Enrollment, and/or anticipated use and/or unwillingness to abstain from PrEP during trial participation Use of post-exposure (...) treatment include symptomatic Neisseria gonorrhea (GC), Chlamydia trachomatis (CT) infection, syphilis, active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic genital warts, chancroid, trichomoniasis. Note: Otherwise eligible participants with an exclusionary UTI may be re-tested during the screening process. At Enrollment, active anorectal infection or RTI requiring treatment per current CDC guidelines (http://www.cdc.gov/std/treatment) or symptomatic UTI. Infections

2018 Clinical Trials

110. Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

(BV) and asymptomatic candidiasis — are offered treatment consistent with WHO recommendations. If treatment is completed and symptoms have resolved within 70 days of obtaining informed assent/consent for screening, the participant may be enrolled. Genital warts requiring treatment also must be treated prior to enrollment. Genital warts requiring therapy are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance, or physical (...) Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Tenofovir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Dapivirine Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents

2018 Clinical Trials

111. Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 45 Years (Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Assigned female sex at birth Note: Participants who are female at birth, who now identify as male, will not be excluded so long as they are not on female-to-male transition therapy. Age 18 through 45 years (inclusive) at Screening, verified (...) for Disease Control and Prevention (CDC) guidelines (http://www.cdc.gov/std/treatment/) at Screening or Enrollment such as gonorrhea, chlamydia, trichomonas, pelvic inflammatory disease, and/or syphilis Note: Genital warts requiring treatment and frequent recurrence of HSV are considered exclusionary; however, infrequent HSV outbreaks are not. Genital warts requiring treatment are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance

2018 Clinical Trials

112. Evaluating the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

protocol clinic visit. See the study protocol for US Low risk guidelines. Laboratory Inclusion Values Hemogram/Complete blood count (CBC) Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were assigned female sex at birth, greater than or equal to 13.0 g/dL for volunteers who were assigned male sex at birth. For transgender participants who have been on hormone therapy for more than 6 consecutive months, determine hemoglobin eligibility based on the gender with which they identify (ie (...) , a transgender female who has been on feminizing hormone therapy for more than 6 consecutive months should be assessed for eligibility using the hemoglobin parameters for persons assigned female sex at birth). White blood cell (WBC) count equal to 2,500 to 12,000 cells/mm^3 WBC differential either within institutional normal range or with site physician approval Platelets equal to 125,000 to 550,000/mm^3 Chemistry Chemistry panel: Alanine aminotransferase (ALT) less than 1.25 times the institutional upper

2018 Clinical Trials

113. MKSAP: 34-year-old man with slow-growing lesions

MKSAP: 34-year-old man with slow-growing lesions Condylomata acuminata that is recalcitrant to therapy should be biopsied MKSAP: 34-year-old man with slow-growing lesions | | October 20, 2018 2 Shares Test your medicine knowledge with the , in partnership with the . A 34-year-old man is evaluated for several slow-growing lesions on his penis. He first noticed the wart-like growths 3 years ago, and they have progressively enlarged. He was treated with topical cryotherapy six times and topical (...) , and the incidence is continuing to grow. Condyloma acuminatum is a form of human papillomavirus (HPV) infection in the genital area, most often secondary to HPV 6 and HPV 11. Therapy for condylomata acuminata includes destructive techniques such as cryotherapy, cantharidin, podophyllin, laser therapy, and topical application of salicylic acid. Immune modulators such as imiquimod also can be used. When these lesions are recalcitrant to therapy or large and atypical in appearance, biopsy is essential to establish

2018 KevinMD blog

114. Canadian clinical practice guidelines for acute and chronic rhinosinusitis

and bacterial sinusitis. Vaccines and prophylactic antibiotic therapy are of no benefit. Moderate Strong 22: Allergy testing or in-depth assessment of immune function is not required for isolated episodes but may be of benefit in identifying contributing factors in individuals with recurrent episodes or chronic symptoms of rhinosinusitis. Moderate Strong Chronic Rhinosinusitis 23 : CRS is diagnosed on clinical grounds but must be confirmed with at least 1 objective finding on endoscopy or computed (...) spending, and economic impact in terms of absenteeism and productivity. It is estimated that approximately 6 billion dollars is spent in the United States annually on therapy for rhinosinusitis [ ]. A recent study in Canada described the impact of chronic rhinosinusitis (CRS) on patients and healthcare utilization [ ]. Patients with CRS had a health status similar to patients with arthritis, cancer, asthma, and inflammatory bowel disease. Compared with people without CRS, those with CRS reported more

2011 CPG Infobase

115. Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

that HPV seropositivity was associated with an increased risk of squamous cell carcinoma of the oropharynx (SCCOP). In addition to SCCOP, another HPV-related health concern is oral warts, a condition for which there is no effective treatment. Even after beginning treatment with highly active antiretroviral therapy (HAART), active HPV replication in the mouth and oropharynx may persist in HIV-infected people, leading to an increased risk of SCCOP and oral warts. The purpose of this study is to evaluate (...) . At baseline and at Week 4, 16, 24, and 48 study visits, participants will undergo an examination of their mouth, throat wash and saliva collection, and behavioral questionnaires. A blood collection will also occur at Week 24. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 500 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy Study Start Date

2009 Clinical Trials

116. Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment

generated. Even tough both genital warts and vulvar intraepithelial neoplasia (VIN) are HPV-associated genital lesions they differ in their risk of malignant progression. Imiquimod (IMQ) is a topically applied Toll-like receptor (TLR) 7 agonist that has been approved for the treatment of superficial (pre-) carcinomas of the skin (basal cell carcinomas, actinic keratosis) and HPV-associated lesions (genital warts). It acts by activation of the immune system exerting anti-tumor and anti-viral properties (...) Model: Single Group Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment Official Title: An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts Study Start Date : December 2008 Actual Primary Completion Date : December 2009 Actual Study Completion Date : May 2010 Resource links

2009 Clinical Trials

117. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with therapy that is currently accepted as standard. Most of the progress made in identifying curative therapy for childhood cancers has been achieved through clinical trials (...) . Information about ongoing clinical trials is available from the . Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[ ] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary on for specific information about the incidence, type, and monitoring of late

2016 PDQ - NCI's Comprehensive Cancer Database

118. Anal Cancer Prevention (PDQ®): Health Professional Version

cell lesions, HPV-16 was present in about two-thirds and HPV-18 was present in about 5%.[ ] Because 85% of anal cancers have a squamous cell carcinoma histology or histologic variant,[ ] it is probable that elimination of oncogenic HPV infection would nearly eradicate anal cancer. HPVs are typically cleared rapidly in healthy individuals. Persistence of the oncogenic HPV strains is more likely in persons with compromised immune systems; therefore, risk of squamous cell anal cancer is much higher (...) ).[ ] Anal cancer risk is positively associated with severity of immunosuppression in HIV-positive and AIDS patients.[ ] When combined antiretroviral therapy (cART) became available in 1996, the incidence of anal cancer among these patients was expected to decrease. While decreases have been observed for other HIV-associated cancers, such trends have not been observed for anal cancer. It has been proposed that timing of cART treatment influences the risk of anal cancer, and that to be effective against

2016 PDQ - NCI's Comprehensive Cancer Database

119. KHA-CARI adaptation of the KDIGO Guideline for the Care of Kidney Transplant Recipients

-CARI Guidelines The Children‘s Hospital at Westmead Locked Bag 4001, Westmead NSW 2145 The KHA-CARI Guidelines – Caring for Australasians with Renal Impairment KHA-CARI Adaptation of KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients (February 2012) Page 1 Table of Contents INTRODUCTION 3 Topic 1. Induction Therapy 8 Topic 2. Initial Maintenance Immunosuppressive Medication 17 Topic 3. Long-Term Maintenance Immunosuppressive Medications 25 Topic 5. Monitoring (...) of morbidity and mortality for the recipients. Therefore the choice of the initial maintenance IS should be a balance between efficacy and tolerance of the IS drugs used in association and targeted to the need of the recipient (immunized vs. non-immunized). (Evidence level B) C. Initial maintenance IS should be administered before transplantation (for living-related graft), or at time of transplantation but before vascular anastomosis (for cadaver graft). IS must be continued daily forever. However

2012 KHA-CARI Guidelines

120. Homeopathy in the paediatric population

, Smolle J. Homeopathic versus placebo therapy of children with warts on the hands: A randomized double-blind clinical trial. Dermatology 1996;193:318-20. Labrecque M, Audet D, Latulippe LG, Drouin J. Homeopathic treatment of plantar warts. CMAJ 1992;146:1749-53. Smolle J. Homeopathy in dermatology. Dermatol Ther 2003;16:93-7. Oberbaum M, Yaniv I, Ben-Gal Y, et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis (...) one or more natural health products and 19% consulted a CAM practitioner . Homeopathy is one of the more popular alternative therapies used in children . The present statement reviews the principles of homeopathy and the evidence, or lack thereof, for its use in specific paediatric conditions. Its purpose is to enable physicians, health care workers and families to make appropriate patient-management decisions. A systematic review of the current literature was performed using PubMed, CAM on PubMed

2012 Canadian Paediatric Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>